BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced that its Epic Hygiene dental laser, the only hygiene dental laser cleared by the U.S. Food and Drug Administration (FDA) for laser bacterial reduction, has been awarded Cellerant’s 2023 Best of Class Hygiene Award.
The Cellerant Best of Class Hygiene Awards program was created by Cellerant Consulting and its founder and CEO Lou Shuman, DMD, CAGS, to honor standout dental products designed for use during dental hygiene appointments. The Cellerant Best of Class Technology Awards identify and acknowledge the top technologies in dentistry and recognize innovative products that set a standard of quality in their respective categories.
The Cellerant Best of Class Hygiene Award selection panel consists of nine renowned thought leaders and educators who, over the course of each year, will seek out and conduct research on potentially practice-changing technologies, with deliberations on nominees and final voting taking place in February. Panelists are precluded from voting in any category where they have consulting relationships.
The entire selection process is conducted and managed on a not-for-profit basis.
“Our dental laser technology enables dentists to enhance the standard of care and improve patient outcomes while advancing the quality of life,” said John Beaver, BIOLASE president and CEO. “Now, more than ever, with the knowledge gained from the pandemic, ensuring a safer work environment is critical to reducing exposure to infectious pathogens and ensuring unimpeded dental care. On behalf of the BIOLASE family, I thank the award’s committee for recognizing the aerosol-free Epic Hygiene dental laser, further validating our leadership position in the hygiene market.”
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 266 patented and 25 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients.
BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2022, BIOLASE has sold over 45,500 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus, Waterlase Express, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE, Waterlase, and Waterlase iPlus are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology.
Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.